Retention rate of Clobazam, Topiramate and Lamotrigine in children with intractable epilepsies at 1 year
| Autor: | I. Ali, William P Whitehouse, Jonathan K.A. Mills, T.G. Lewis, A. Ugur, K. Mughal |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Sleep Wake Disorders Topiramate Pediatrics medicine.medical_specialty Clobazam Adolescent Clinical Neurology Fructose Lamotrigine Benzodiazepines Epilepsy Humans Medicine Child Adverse effect Retrospective Studies Triazines business.industry Infant Retrospective cohort study General Medicine Exanthema Retention rate medicine.disease Treatment Outcome Neurology Tolerability Child Preschool Anesthesia Patient Compliance Female Neurology (clinical) business medicine.drug |
| Zdroj: | Seizure. 20:402-405 |
| ISSN: | 1059-1311 |
| DOI: | 10.1016/j.seizure.2011.01.011 |
| Popis: | Clobazam (CLB), Topiramate (TOP) and Lamotrigine (LAM) are newer second-line antiepileptic drugs (AEDs) used in children. This is a single-centre retrospective observational study of the efficacy, tolerability and retention rate in 224 separate treatment episodes in 194 children, aged 0.1-16.7 years (median 9.4) over an 8 year period. The median age of epilepsy onset was 3.3 years (range 0-15.1). 79% started CLB, TOP or LAM as at least the 3rd AED, with 39% having been withdrawn from at least 2 AEDs. 53% had generalised and 37% idiopathic epilepsies. The maintenance doses for CLB ranged 0.12-3.50 mg/kg/day (mean 0.7); for TOP 0.45-32.0 mg/kg/day (mean 7.1) and for LAM 1.13-16.0 mg/kg/day (mean 5.6). The study comprised 75 person-treatment years for CLB, 56 for TOP, 124 for LAM.CLB, TOP and LAM were well tolerated with 51%, 37% and 69% remaining on treatment beyond 1 year respectfully. 1 serious adverse event for CLB (inducing seizures) and 2 for LAM (rashes) were reported, and 60%, 47% and 39% had possibly and probably related adverse events for CLB, TOP and LAM respectively. Beyond 12 months seizure improvement (50% seizure frequency compared to baseline) was reported in 43%, 35% and 44% on CLB, TOP and LAM, including 5% and 8% remaining seizure free on CLB and LAM respectively.Our results demonstrate the efficacy and tolerability of CLB, TOP and LAM in children with difficult to treat epilepsies and a good response in CLB and LAM, and a reasonable response in TOP beyond 12 months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect